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Objectives The aim of this study was to examine the frequency and causes of surgical explantation
of patent foramen ovale (PFO) closure devices.
Background PFO has been linked with cryptogenic strokes, recurrent transient neurologic deﬁcits,
leep apnea, decompression illness, and migraines. Several randomized trials are in progress to de-
ermine whether PFO closure is preferable to medical management in the treatment of patients
ith cryptogenic strokes or migraine. The majority of PFO closures are performed off-label, because
here is no U.S. Food and Drug Administration approval for use of any device to close a PFO. As
ata are accumulating on the beneﬁts of implanting PFO closure devices, it is also important to ex-
mine complications that might occur.
ethods We performed a database review to identify the frequency and causes of PFO device ex-
lantation, examining 18 PFO closure centers in Europe and the United States.
esults Of the 13,736 percutaneous PFO device implantations performed over the past 9 years at
hese 18 institutions, 38 devices (0.28% [95% conﬁdence interval: 0.20% to 0.37%]) required surgical
emoval. There were a wide range of causes cited for these removals. The most common cause for
xplantation was chest pain (n  14), often determined to be secondary to nickel allergy to the PFO
device. Other causes for explantation included persistence of a residual shunt (n  12), the presence
of thrombus on the device (n  4), pericardial effusion (n  2), perforation of the atrium or aortic
root (n  2), recurrent strokes (n  1), the development of endocarditis (n  1), and undocu-
mented reasons (n  2).
Conclusions The vast majority of PFO closure procedures are performed safely with minimal complications.
However, there is a small (0.28%) incidence of severe long-term problems associated with PFO closure that
might require surgical removal of the device. In addition, the frequency of surgical explantation was found to
be device-dependent; some of these devices seem to be safer than others. (J Am Coll Cardiol Intv 2011;4:
579–85) © 2011 by the American College of Cardiology Foundation
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580Patent foramen ovale (PFO) is associated with cryptogenic
strokes, recurrent transient neurologic deficits, sleep apnea,
decompression illness, and migraines (1). Approximately
20% of adults have a PFO (2), and it is estimated that 8,000
PFO closure procedures are performed each year in the
United States, with various devices (3).
Percutaneous closure of PFO is very effective, with nearly
90% of patients displaying complete closure of their PFO
after 1 year (4). Multiple observational studies describe the
apparent safety of PFO closure with percutaneous devices
(5). Several randomized trials are in progress to determine
whether PFO closure is preferable to medical management
in the treatment of patients with cryptogenic strokes or
migraine, with respect to efficacy as well as safety (6,7).
As data are accumulating on the benefits of implanting
FO closure devices, it is important to also examine
omplications that might occur. Currently, there is no U.S.
ood and Drug Administration approval for any PFO closure
ndication; nevertheless, PFOs are being closed off-label with-
ut a clear understanding of the relative frequency of compli-
ations. There have been isolated reports of patients that
eeded to have their device removed. Because extraction of a
PFO device requires open heart
surgery, we wanted to determine
the relative frequency of this un-
toward event.
Methods
A retrospective survey was per-
formed to identify the frequency
and causes of PFO device ex-
plantation by examining 18 PFO closure centers in Europe
and the United States. The total number of PFO device
implantations was obtained from each institution. The
number of patients who underwent surgical explantation of
their device was determined. The information was obtained
from each institution as an aggregate total number of
explants and total number of implants without personal
identifiers attached. This study was approved by the re-
search review board of each institution. The time period
covered was different for each institution but includes all
cases that were performed at that institution. Because this
was a retrospective, self-reporting study, underreporting has
to be assumed.
Data were obtained on the type of device used for
implantation, type of device that was explanted, and the
causes for explantation. Information was also obtained with
regard to patients who had prolonged chest pain (1 year)
ut who did not undergo device explantation. This registry
id not address device closure of atrial septal defects
ASDs), which might have a higher rate of surgical explan-
Abbreviations
and Acronyms
ASD  atrial septal defect
CI  confidence interval
FO  patent foramen ovale
EE  transesophageal
chocardiogramation.Results
There were 13,736 devices implanted among the 18 centers
over the past 3 to 9 years. Amplatzer (AGA Medical
Corporation, Golden Valley, Minnesota) devices were used
in 9,109 (66%) of the procedures. CardioSEAL (NMT
Medical, Boston, Massachusetts) devices were implanted in
2,023 (15%) patients. Helex (W.L. Gore and Associates,
Flagstaff, Arizona) devices were employed in 1,201 (9%)
implantations, and 1,403 (10%) other devices were used,
including Sideris (Custom Medical Devices, Amarillo,
Texas), PFO Star (Cardia, Inc., Burnsville, Minnesota),
Occlutech (International Occlutech AB, Helsingborg, Swe-
den), Solysafe (Swissimplant AG, Solothurn, Switzerland),
Premere (St. Jude Medical, Maple Grove, Minnesota),
FigullaFlex (International Occlutech), Cierra (Cierra, Red-
wood City, California), Coherex (Coherex, Salt Lake City,
Utah), Angelwings (Microvena Corporation, White Bear
Lake, Minnesota), SeptRX (SeptRX, Fremont, California),
or BioStar (NMT Medical).
There were a total of 38 devices explanted at these institutions.
The 19 Amplatzer devices accounted for 50% of the explanted
devices, and the 16 CardioSEAL devices accounted for 42%, but
the frequency of explantation is device-dependent. There were 2
(5%) Helex devices that were surgically excised. There was also 1
(3%) incident of 1 of the lesser-used devices (Sideris) that was
explanted. A summary of the results from this self-reporting
survey are provided in Tables 1, 2, and 3.
Among the 38 total explantations, 14 (37%) patients
underwent surgical excision of their device for chest pain,
and of these, 7 (18%) had nickel allergy, 12 (32%) devices
were explanted because of the persistence of a residual
shunt; 4 (11%) patients had the device removed secondary
to thrombus formation on the device, and 2 (5%) devices
were taken out because of pericardial effusion. Erosion was
responsible for 2 (5%) devices being explanted. Recurrent
stroke accounted for the removal of 1 (3%) PFO closure
device, 1 (3%) device was excised secondary to development
of an infection stemming from the device, and 1 (3%) was
removed due to the persistence of migraine symptoms.
There was 1 (3%) device taken out due to an unspecified cause. In
addition to the 38 patients who underwent explantation, there
were 3 patients with prolonged chest pain (1 year) who did not
Table 1. Type of Device, Number of Implants and Explants Reported
CardioSEAL Amplatzer Helex Other Total
Implantations 2,023 9,109 1,201 1,403 13,736
Explantations 16 19 2 1 38
% explanted 0.79% 0.21% 0.17% 0.07% 0.28%
Amplatzer (AGA Medical Corporation, Golden Valley, Minnesota); CardioSEAL (NMT Medical,
Boston, Massachusetts); Helex (W.L. Gore and Associates, Flagstaff, Arizona). The difference be-
tween the frequency of explanted Amplatzer and CardioSEAL devices is statistically significant(chi-square 17.9, p 0.00003).
ifornia a
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581undergo surgical excision of their device, but surgery was discussed
with the patient. In 1 patient, the symptoms resolved gradually
after 1 year, and another patient was lost to follow-up.
Of the 14 cases of chest pain, 10 (71%) patients had
Amplatzer devices, 2 (14%) patients had CardioSEAL devices,
and 2 (14%) patients had Helex devices. Nickel allergy was
present in 7 of these 14 patients with chest pain, as docu-
mented by a reaction to the TRUE (Allerderm, Phoenix,
Arizona) skin patch test. All 7 of these patients had Amplatzer
devices in place, and treatment was attempted with clopidogrel,
steroids, and/or non-steroidal anti-inflammatory drugs before
undergoing surgical explantation of their device. Of the 14
Table 2. Implantations and Explantations/Device by Institution
Implantations
Institution AMP CS HX
Brescia, Italy 750 0 0
Columbia University 4 1,104 73
Emory University 225 0 5
Evanston Hospital 42 0 53
Intermountain Medical Center, SLC 1,529 246 250
Mayo Clinic, Rochester 660 3 32
Rush University 600 0 150
Sankt Katharinen, Frankfurt, Germany 1,635 27 485
Swedish Medical Center 35 211 0
UCLA 150 35 45
UMDNJ, Cooper University Hospital 125 40 0
University Hospital, Bern, Switzerland 1,350 20 5
University of Colorado 425 25 0
University of Milan, Italy 348 0 0
University of Pennsylvania 115 105 5
University of Utah 484 35 91
University of Washington 92 112 7
Washington University, St. Louis 540 60 0
Total 9,109 2,023 1,201
Explantations were not necessarily performed at the same institution where the devices were impl
AMP Amplatzer; CS CardioSEAL; HX Helex; SLC Salt Lake City; UCLA University of Cal
Table 3. Reasons for Explantation/Device
Amplatzer
(n  9,109)
CardioSEAL
(n  2,023
Chest pain 10 (0.11%) 2 (0.10%)
Residual shunt 4 (0.04%) 8 (0.40%)
Thrombus 1 (0.01%) 3 (0.15%)
Perforation 1 (0.01%) 1 (0.05%)
Pericardial effusion 2 (0.02%) 0
Recurrent stroke 0 1 (0.05%)
Infection 0 1 (0.05%)
Other 1 (0.01%) 0
Total 19 (0.21%) 16 (0.79%)
Percentages represent the number of specific devices explanted/specn number of implantations performed, with respect to each specific devipatients with chest pain, there were 7 who were not tested for
nickel allergy and therefore were designated as having refrac-
tory chest pain of unknown etiology. Of the 7 patients who
were not tested for nickel allergy, 3 had Amplatzer devices,
including an individual determined to have coronary sinus
obstruction. This patient began experiencing chest pain on
exertion 1 month after the procedure. The 35-mm Amplatzer
PFO Occluder (the largest available size) was explanted 6
months after the closure procedure. CardioSEAL devices were
placed in 2 of the patients. There was also 1 case of a 25-mm
Helex device that was removed 3 weeks after implantation, for
intractable chest pain. There was 1 other case of a Helex device
Explantations
er Total AMP CS HX Other Total
10 860 2 0 0 0 2
2 1,183 0 3 1 0 4
20 250 0 0 0 0 0
3 98 0 0 0 0 0
0 2,025 4 1 0 0 5
0 695 0 0 0 0 0
0 750 0 0 0 0 0
28 3,275 1 0 0 0 1
0 246 1 3 0 0 4
0 230 3 2 1 0 6
0 165 0 0 0 0 0
25 1,500 0 0 0 1 1
0 450 0 0 0 0 0
15 363 0 0 0 0 0
0 225 1 1 0 0 2
0 610 3 0 0 0 3
0 211 1 0 0 0 1
0 600 1 2 0 0 3
03 13,736 19 16 2 1 38
t Los Angeles; UMDNJ University of Medicine and Dentistry of New Jersey.
Helex
(n  1,201)
Other
(n  1,403)
Total
(n  13,736)
2 (0.17%) 0 14 (0.10%)
0 0 12 (0.09%)
0 0 4 (0.03%)
0 0 2 (0.01%)
0 0 2 (0.01%)
0 0 1 (0.01%)
0 0 1 (0.01%)
0 1 (0.08%) 2 (0.01%)
2 (0.17%) 1 (0.08%) 38 (0.28%)
ices implanted.Oth
1
1,1
1
1,4
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582being explanted 6 months after closure for complaints of chest
pain and new onset atrial fibrillation.
In addition to the 14 individuals who had their devices
removed because of chest pain, there were 2 other patients
that had their devices taken out for a large residual shunt (1
Amplatzer, 1 CardioSEAL) who also complained of chest
pain. The chest pain symptoms resolved in all 16 patients
who underwent surgical explantation of their device.
There were 12 (0.09%) instances of explantation second-
ary to residual shunt, relative to the 13,736 implantations; 8
of these procedures were for CardioSEAL devices (0.40% of
such devices), and 4 were for Amplatzer devices (0.04%). In
all of these cases, there were indications of device malposi-
tion or new atrial tears that directed the operators to choose
explantation instead of placement of a second device.
Thrombus formation on the device was the justification
for surgical excision in 4 (0.03%) of the 13,736 device
implants. Of the 4 devices explanted with thrombus in the
current study, 3 were CardioSEAL devices (0.15% of such
devices) and 1 was an Amplatzer device (0.01%).
Of the 13,736 individuals who underwent implantation of
PFO closure devices, there were 2 (0.01%) patients found to have
perforations; 1 occurred just hours after aCardioSEALdevice was
implanted. This could have been due to the implantation proce-
dure or trauma from the device itself. The second patient had an
Amplatzer PFO 25-mm device removed for a late erosion,
without any symptomatic complaints. There were 2 (0.01%)
patients with Amplatzer devices explanted for effusion and con-
cern for possible erosion. Pericardial effusion has been observed in
patients with nickel allergy, but testing for nickel allergy was not
performed on either of these patients.
There was only 1 (0.01%) patient who had the device
removed because of a recurrent stroke after the device was in
place. This CardioSEAL device was noted on transesophageal
echocardiogram (TEE) to be distorted, and the recurrent
stroke was suspected to be secondary to the persistence of a
right-to-left shunt after the closure procedure, but a residual
thrombus on the device could not be excluded.
In this study of over 13,000 patients, there was only 1 (0.01%)
patient who developed endocarditis around the device, which led
to surgical explantation of a CardioSEAL device.
There were 2 (0.01%) other patients that had their device
removed; 1 was an Amplatzer device removed because of exacer-
bation of migraine symptoms. Testing for nickel allergy was not
performed on this patient. The other was a lesser-used, Sideris
device, explanted for an undocumented reason.
Amplatzer devices were removed in a total of 19 (0.21%
[95% confidence interval (CI): 0.13% to 0.33%]) of the 9,109
patients who received the Amplatzer device. CardioSEAL
devices were explanted in 16 (0.79% [95% CI: 0.49% to
1.28%]) of the 2,023 patients who had this device implanted.
The difference between the frequency of explanted Amplatzer
and CardioSEAL devices is statistically significant (chi-square
7.9, p 0.00003). Two of the 1,201 (0.17% [95% CI: 0.02%o 0.46%]) Helex devices were taken out, which is a signifi-
antly lower rate than the CardioSEAL devices (chi-square
.2, p 0.008). The CardioSEAL implant was removed with
frequency that is 4 times as high as the Amplatzer and 5
imes the frequency of the Helex device.
A representative case example might be useful to under-
tand the reasoning behind the decisions to perform open-
eart surgery in these patients.
Case example. A 49-year-old woman presented with history of
episodic migraine headaches with visual aura since age 7. At age
45, she had a transient neurologic deficit consisting of an altered
state of consciousness, total global amnesia, dizziness, and apraxia.
The clinical evaluation revealed a PFO with no evidence of
atherosclerotic disease. An Amplatzer 25-mm Cribriform ASD
closure device was implanted without difficulty.
Within 3 months after the procedure, there was an
increase in the frequency (3 per month) and intensity of her
migraines. The patient also developed intermittent chest
discomfort around the xiphoid area that occurred at rest and
was exacerbated by lying on her left side or by exertion. She
also experienced episodes of shortness of breath and palpi-
tations, usually lasting a few minutes. The chest pain
progressed in severity and became constant.
One year after PFO closure, the patient moved to another
city and was diagnosed with a nickel allergy, manifested by
a significant blister reaction to a TRUE skin patch test. A
transcranial Doppler study revealed a grade 4/5 right-to-left
shunt. A course of clopidogrel and prednisone was attempted.
Severe chest pain persisted, requiring emergency department
visits for pain control. Medical therapy was unsuccessful for
her chest pain or headaches and she underwent surgical
excision of the Amplatzer device (Fig. 1) with insertion of a
bovine pericardial patch. A small fenestration in the atrial
septum was observed inferior to the Amplatzer device,
which accounted for the persistent right-to-left shunt.
Pathological examination revealed extensive fibrosis with
scattered eosinophils and inflammatory cells. After the
explantation, the chest pain resolved, and the migraines
were reduced to 2 episodes in 6 months.
The residual shunt might have accounted for her recurrent
headache but not the chest pain. By contrast, nickel allergy could
explain both recurrent headache as well as severe chest pain due to
excessive inflammation. This device was implanted at another
institution, so it is unknown whether this small hole was a
fenestration that was originally there. The fenestration was not
immediately adjacent to the Amplatzer device, and so it did not
seem at surgery to be due to erosion.
Discussion
The various PFO devices can be inserted percutaneously
with a high degree of success and a low complication rate.
Although the randomized trials are not completed yet, the
observational reports of the effect of PFO closure have been
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583very positive. Therefore, many PFO devices are implanted
each year off-label despite the absence of U.S. Food and
Drug Administration approval. However, it is important to
understand the potential risks associated with this proce-
dure. One of these risks is the possibility of the need for
open-heart surgery to remove these implanted devices.
Indications for surgical removal might include perforation
of the atrial wall, intracardiac thrombosis, device emboliza-
tion, deformation of the device umbrellas, fatigue fractures
Figure 1. Amplatzer 30-mm Cribriform ASD Occluder and H and E Stain
(A) Amplatzer 30-mm Cribriform ASD Occluder (AGA Medical Corporation, Gol
occluder reveals extensive ﬁbrosis especially on the left atrial (LA) side. (B) He
inﬂammatory cells with occasional eosinophils.of the metal struts, presence of post-procedural shunts,prolonged chest pain, and allergic reactions to nickel within
the device. Although there are a variety of reasons that
might lead to explantation of a PFO device, there are only
a small percentage of cases that eventually need to have the
device removed. In this survey of 13,736 cases from 18
centers in Europe and the United States, there were 38
(0.28% [95% CI: 0.20% to 0.37%]) cases that required
surgical removal of the PFO device.
It is possible that nickel allergy could have been an under-
alley, Minnesota). The explanted 30-mm Cribriform atrial septal defect (ASD)
alin and eosin (H and E) staining demonstrate intense ﬁbrosis with mildden V
matoxlying cause in almost one-half of the patients who underwent
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584explantation, because many of those patients who had chest
pain or effusion were not tested for nickel allergy. There is
disagreement as to the optimal method of testing for nickel
allergy, which occurs in 10% to 15% of the population, and
whether a cutaneous reaction to a patch test corresponds to an
allergic reaction within the bloodstream (8–10). Some studies
also suggest that the rise of nickel levels in the blood can only
be observed for a few weeks after implantation; therefore,
associated symptoms persisting for several months cannot
reliably be linked to nickel allergy (11–13). However, the
mechanism of nickel allergy to an indwelling device is not
well-understood and might not depend only on the solubility
of nickel ions. Although there does not seem to be a perfect
correlation, the TRUE patch test in our experience seems to
identify those patients who have a higher incidence of an
exaggerated inflammatory reaction to the Amplatzer devices
manifested by chest pain and migraine headaches after implan-
tation (14).
Residual shunt was the second-most-common cause for
explantation of PFO closure devices in our study. Although
a small residual shunt is not uncommon immediately after
the procedure, most of the shunts disappear in the subse-
quent 3 to 6 months as fibrous tissue develops around the
device allowing for complete closure of the PFO. However,
some devices report a high incidence of large residual
shunts; for example, the CardioSEAL is reported to have a
large residual shunt in 15% of cases (15). In some instances,
another device has been implanted adjacent to the original
apparatus, resolving the residual shunt (16). The cases de-
scribed in this series were large shunts that the operators felt
were not amenable to a second percutaneous device for various
reasons. The decision to explant the devices was left up to the
individual operators.
Some patients underwent explantation of their device after
thrombus was visualized on the device during follow-up
echocardiography. Most of these cases resolve with medical
therapy and do not require surgical removal. Thrombus for-
mation is seen in 0% to 7% of patients who undergo percutaneous
PFO closure but is variable and depends on the type of device
(e.g., thrombus has been observed by TEE in 7% to 23% of
CardioSEAL cases) (17,18). Because post-procedure TEE was
not performed routinely at these centers, the incidence of throm-
bus on the different devices in this survey is not known.Only those
patients who had very large thrombus and/or embolic phenome-
non were likely to undergo surgical explantation of the device.
Perforation of the atrium or aortic root has been associ-
ated with the Amplatzer ASD device, but there are only 5
case reports of perforation due to the PFO closure device
(19–23). Pericardial effusion can also be a sign of the
inflammatory response from nickel allergy; therefore, the
presence of a pericardial effusion does not necessarily indi-
cate that erosion has occurred.
The persistence of symptoms after implanting the PFO
closure device can indicate device malposition or a possiblesecond defect in the atrial wall. This is sometimes seen in
patients who continue to complain of migraines, have
recurrent strokes, or transient neurologic deficits. This
might be resolved by placing a second device into the heart,
but it was noted as one of the causes for explantation. The
decision to proceed with surgical explantation is variable,
depending on the practice of the physician and the subjec-
tive level of discomfort of the patient.
Study limitations. It should be emphasized that this is a
self-reporting, retrospective survey that could lead to several
biases. The true prevalence of device explantation is prob-
ably underestimated because of underreporting. With this
type of retrospective analysis, follow-ups might not have
been complete (e.g., patients might have moved). Patients
who underwent surgical explantation might not have had
their device implanted at the same institution. One of the
biases in this study is that it focused on selected centers that
were willing to participate and had a database of patient
follow-up and does not attempt to encompass all the devices
that have been implanted worldwide. However, it is unlikely
that a prospective trial will ever be performed with the
number of cases that is described in this paper. Therefore,
this retrospective survey provides the best chance to estimate
the frequency of explantation for the various PFO devices.
Conclusions
The vast majority of PFO closure procedures are performed
safely with minimal complications. However, there is a
small incidence (0.28% [95% CI: 0.20% to 0.37%]) of severe
adverse reactions associated with PFO closure devices that
require surgical removal. In this compilation of over 13,000
cases from 18 clinical centers, the most common reason
given for explantation was severe persistent chest pain,
which might be related to nickel allergy in some patients.
Other causes for explantation included recurrent stroke,
persistence of a residual shunt, the presence of an intracar-
diac thrombus, erosion of the device with perforation of the
atrium or aortic root, and the development of endocarditis.
Only randomized clinical trials can provide unbiased data
as to the relative benefit of PFO closure with a device
compared with medical therapy. Surgical removal of PFO
closure devices is rare (1 in 361 cases in this series) but
requires open-heart surgery. However, the frequency of
removal seems to be device-dependent: in this survey the
rate of explantation was 1 in 126 for CardioSEAL devices,
1 in 480 for Amplatzer devices, and 1 in 600 for the Helex
device. Patients should be made aware of the possibility of
device explantation when informed consent is obtained. This
retrospective analysis provides practical information for the patient
and physician about the approximate frequency of these compli-
cations that can result in surgical explantation.
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